Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis Products Under its Newly Expanded Cultivation License
November 14 2024 - 7:00AM
UK Regulatory
Tilray Medical Launches its First Commercial “Grown in Germany”
Medical Cannabis Products Under its Newly Expanded Cultivation
License
NEUMÜNSTER, Germany, Nov. 14, 2024 (GLOBE
NEWSWIRE) -- Tilray Medical, a division of Tilray Brands,
Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a
global leader in medical cannabis, empowering the therapeutic
alliance between patients and healthcare practitioners to make
informed individualized health decisions, today announced the
launch of its first commercial German grown medical cannabis
flowers from its Aphria RX GmbH (“Aphria RX”) facility. This launch
marks the first medical cannabis products to be grown in Germany by
Aphria RX under the newly issued medical cannabis cultivation
license under MedCanG.
On July 15, 2024, Tilray Medical was the first
to receive a new cannabis cultivation license issued under MedCanG.
This license allows Aphria RX to cultivate and manufacture a broad
range of commercially available medical cannabis in Germany. The
strains to be grown at this indoor facility have been carefully
selected from top performing varieties popular with patients across
Canada.
Tilray's Chief Strategy Officer and Head of
International, Denise Faltischek, said, "We are excited to launch
our Made in Germany premium cannabis products, which marks a
significant milestone in our mission to deliver the highest-quality
medical cannabis products to patients in Germany. This not only
serves to expand Tilray's leadership in medical cannabis
cultivation, production and distribution in Germany but
also proves our commitment to be one of the most responsible,
trusted and market leading cannabis companies in the world with a
portfolio of innovative and high-quality products that address the
needs of patients. We reiterate our appreciation for the trust that
the German Government has placed in Tilray, and we are proud of our
Aphria RX team for their groundbreaking work in medical cannabis
cultivation and patient care."
About Tilray Medical
Tilray Medical is dedicated to transforming
lives and fostering dignity for patients in need through safe and
reliable access to a global portfolio of medical cannabis brands,
including Tilray, Aphria, Broken Coast, Symbios and
Navcora. Tilray grew from being one of the first
companies to become an approved licensed producer of medical
cannabis in Canada to building the first GMP-certified
cannabis production facilities in Europe, first
in Portugal and later in Germany. Today, Tilray
Medical is one of the largest suppliers of medical cannabis to
patients, physicians, hospitals, pharmacies, researchers, and
governments, in 20 countries and across five continents.
For more information on Tilray Medical,
visit Tilray Medical Europe, Tilray Medical
Canada, and Tilray Medical Australia-New
Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq:
TLRY; TSX: TLRY), is a leading global lifestyle and consumer
packaged goods company with operations in Canada, the
United States, Europe, Australia, and Latin
America that is leading as a transformative force at the nexus
of cannabis, beverage, wellness, and entertainment, elevating lives
through moments of connection. Tilray’s mission is to be a leading
premium lifestyle company with a house of brands and innovative
products that inspire joy and create memorable experiences.
Tilray’s unprecedented platform supports over 40 brands in over 20
countries, including comprehensive cannabis offerings, hemp-based
foods, and craft beverages.
For more information on how we are elevating
lives through moments of connection, visit Tilray.com and
follow @Tilray on all social platforms.
Forward-Looking
Statements
Certain statements in this communication
that are not historical facts constitute forward-looking
information or forward-looking statements (together,
“forward-looking statements”) under Canadian securities laws and
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that are intended to be subject to the “safe harbor”
created by those sections and other applicable laws.
Forward-looking statements can be identified by words such as
“forecast,” “future,” “should,” “could,” “enable,” “potential,”
“contemplate,” “believe,” “anticipate,” “estimate,” “plan,”
“expect,” “intend,” “may,” “project,” “will,” “would” and the
negative of these terms or similar expressions, although not all
forward-looking statements contain these identifying words. Certain
material factors, estimates, goals, projections, or assumptions
were used in drawing the conclusions contained in the
forward-looking statements throughout this communication.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses, or current
expectations concerning, among other things: expectations regarding
the performance and scale of the Company, including Tilray Medical;
and the Company’s ability to expand its offering to patients
worldwide, including via Tilray Medical. Many factors could cause
actual results, performance, or achievement to be materially
different from any forward-looking statements, and other risks and
uncertainties not presently known to the Company or that the
Company deems immaterial could also cause actual results or events
to differ materially from those expressed in the forward-looking
statements contained herein. For a more detailed discussion of
these risks and other factors, see the most recently filed annual
information form of Tilray and the Annual Report on Form
10-K (and other periodic reports filed with the SEC)
of Tilray made with the SEC and available on
EDGAR. The forward-looking statements included in this
communication are made as of the date of this communication and the
Company does not undertake any obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events, or otherwise unless required by applicable securities
laws.
For further information:
Media: news@tilray.com
Investors: investors@tilray.com
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Nov 2024 to Dec 2024
Tilray Brands (TG:2HQ)
Historical Stock Chart
From Dec 2023 to Dec 2024